The Life Sciences and Public M&A teams advised Obsidian Therapeutics, Inc. in its definitive merger agreement with Galera Therapeutics, Inc. (OTC: GRTX) in an all-stock transaction, pursuant to which both companies will become wholly owned subsidiaries of a newly formed company that will operate as Obsidian Therapeutics, Inc. The transaction is supported by an oversubscribed $350 million concurrent private placement financing from a syndicate of new and existing investors, expected to close immediately prior to the completion of the merger and to fund the combined company’s operations into the second half of 2028, supporting the advancement of Obsidian’s pipeline of engineered tumor-infiltrating lymphocyte (TIL) cell therapies.
Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered TIL cell therapies for the treatment of patients with solid tumors. Obsidian’s proprietary cytoDRiVE™ platform is highly versatile and allows the company to leverage drug responsive domains, or DRDs, to control protein function, with their initial focus on TIL cell therapies developed from this platform, or cytoTILs™.
The Goodwin team was led by Bill Collins, Tevia Pollard, and Gabriela Morales-Rivera and included Andrew Yu, Andrea Akinbola, Timbre Griffin, Keerthi Adusumilli, Madeleine Popp, Claire Treesh, Haylee Brown, Erini Svokos, Katerina Stavrianidis, Steven Tjoe, Krupa Zachariah, Matthew Wetzel, Dustin Schaefer, Tim Worden, Lucy Sharples, Oliver Samuel Walker, Alexandra Denniston, Greg Matisoff, Austin Fahnestock, Timothy Holahan, Brendan Lally-McGurl, Daniel Karelitz, Devan Greevy, Arman Oruc, Simone Waterbury, Jim Matarese, Jonathan Burr, Caroline Bullerjahn, and John Barker.
For more information, please read the press release.